Holen Sie sich die Stockscreener-App
3.19
5.63%
0.17
Handel nachbörslich:
3.20
0.01
+0.31%
Schlusskurs vom Vortag:
$3.02
Offen:
$3.02
24-Stunden-Volumen:
3.76M
Relative Volume:
0.82
Marktkapitalisierung:
$1.03B
Einnahmen:
$360.78M
Nettoeinkommen (Verlust:
$-23.91M
KGV:
-40.85
EPS:
-0.0781
Netto-Cashflow:
$13.07M
1W Leistung:
-6.73%
1M Leistung:
-10.39%
6M Leistung:
+15.16%
1J Leistung:
-39.01%
1-Tages-Spanne:
$2.995
$3.20
1-Wochen-Bereich:
$2.895
$3.405
52-Wochen-Spanne:
$2.23
$6.51
Mannkind Corp Stock (MNKD) Company Profile
Firmenname
Mannkind Corp
Sektor
Branche
Telefon
818-661-5000
Adresse
1 CASPER STREET, DANBURY, CA
Compare MNKD vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
3.19 | 1.03B | 360.78M | -23.91M | 13.07M | -0.0781 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-27 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-11-13 | Eingeleitet | Leerink Partners | Outperform |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-10-10 | Eingeleitet | Leerink Partners | Outperform |
| 2025-07-16 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-02-10 | Eingeleitet | Wedbush | Outperform |
| 2024-12-20 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-19 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-10-10 | Eingeleitet | Wedbush | Outperform |
| 2021-05-14 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-24 | Eingeleitet | Oppenheimer | Outperform |
| 2019-10-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-05-14 | Eingeleitet | BTIG Research | Buy |
| 2019-03-04 | Eingeleitet | SVB Leerink | Outperform |
| 2019-02-22 | Eingeleitet | SVB Leerink | Outperform |
| 2018-02-28 | Herabstufung | Maxim Group | Hold → Sell |
| 2017-11-01 | Herabstufung | Maxim Group | Buy → Hold |
| 2017-10-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-10-06 | Bestätigt | Maxim Group | Buy |
| 2017-08-11 | Eingeleitet | Maxim Group | Buy |
| 2016-05-10 | Bestätigt | Piper Jaffray | Underweight |
| 2016-05-10 | Bestätigt | RBC Capital Mkts | Underperform |
| 2016-01-06 | Bestätigt | Piper Jaffray | Underweight |
| 2016-01-06 | Bestätigt | RBC Capital Mkts | Underperform |
| 2015-11-04 | Herabstufung | RBC Capital Mkts | Outperform → Underperform |
| 2015-09-09 | Herabstufung | Piper Jaffray | Neutral → Underweight |
| 2015-08-03 | Bestätigt | RBC Capital Mkts | Outperform |
| 2015-05-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2015-05-11 | Bestätigt | MLV & Co | Hold |
| 2015-04-16 | Bestätigt | RBC Capital Mkts | Outperform |
Alle ansehen
Mannkind Corp Aktie (MNKD) Neueste Nachrichten
MannKind to Participate in the Chardan Healthcare Conference - GlobeNewswire Inc.
A heart-failure injector delivers a full dose in under 10 seconds. Urine output was similar to treatment into a vein. - Stock Titan
New data supports Furoscix ReadyFlow autoinject... - Pluang
MannKind Presents New Data Showing Furoscix ReadyFlow Delivers IV-Equivalent Diuresis Across Injection Sites at HFSA 2026 - Quiver Quantitative
MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD) - GlobeNewswire Inc.
MNKD Maintains Buy Rating -- Price Target Lowered to $5.00 by Truist Securities - GuruFocus
MannKind stock weighs 43 percent revenue growth against losses - AD HOC NEWS
Delaware Court Ruling Boosts MannKind (MNKD) Outlook Amid Liquid - GuruFocus
MNKD Stock Draws Trader Focus On Rose Pharma GLP-1 Deal - StocksToTrade
MNKD Stock In Focus After Rose Pharma GLP-1 Licensing Deal - timothysykes.com
MNKD Stock In Focus After Rose Pharma GLP-1 Licensing Deal - timothysykes.com
Steven Binder sells $128,477 of MannKind (MNKD) stock By Investing.com - Investing.com South Africa
Director Steven Binder Sells 39,051 Shares of MannKind Corp (MNK - GuruFocus
Steven Binder sells $128,477 of MannKind (MNKD) stock By Investing.com - Investing.com Nigeria
Form 4 MannKind Corp For: 28 September By Investing.com - Investing.com Nigeria
Steven Binder sells $128,477 of MannKind (MNKD) stock - Investing.com
Steven Binder sells $128,477 of MannKind (MNKD) stock By Investing.com - Investing.com Canada
Form 144 MannKind Corporation For: 25 September - Investing.com India
Form 144 MannKind Corporation For: 25 September By Investing.com - Investing.com Canada
Shares valued at $128,478 are proposed for sale by MannKind (MNKD) director Steven Binder. - Stock Titan
Danbury Company Reports Positive Results In Lung Disease Drug Trial - Patch
MannKind Corporation (MNKD) Options ChainYahoo Finance - Yahoo! Finance Canada
MannKind Corporation (MNKD) Stock Analysis: Exploring a 127.68% Potential Upside in the Biotech Space - DirectorsTalk Interviews
MNKD Stock Rises 8% On Furoscix ReadyFlow Approval And $50M Funding Boost - Stocktwits
Mannkind Stock Price Forecast. Should You Buy MNKD? - StockInvest.us
MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum - TradingView
MannKind (MNKD) Bets On Inhaled Weight Loss Amid Widening Losses - Yahoo Finance
Cantor Fitzgerald reiterates Overweight on MannKind stock at $8 By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Overweight rating on MannKind stock By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Overweight on MannKind stock at $8 By Investing.com - Investing.com South Africa
Cantor Fitzgerald reiterates Overweight rating on MannKind stock By Investing.com - Investing.com Canada
Cantor Fitzgerald reiterates Overweight on MannKind stock at $8 By Investing.com - Investing.com India
Cantor Fitzgerald reiterates Overweight rating on MannKind stock - investing.com
MNKD Reiterates by Cantor Fitzgerald -- Price Target Maintained at $6.50 - GuruFocus
MannKind (NASDAQ: MNKD) director lines up more stock sales under trading plan - stocktitan.net
CT drugmaker partners on development of inhaled weight-loss treatment - Hartford Business Journal
MannKind inks obesity deal with Rose Pharma - thepharmaletter.com
Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule - Benzinga
MannKind signs global GLP-1 inhalation collaboration deal - grafa.com
MannKind Expands Into Weight Loss With Rose Pharma Deal – Here’s What Investors Are Watching - Yahoo Finance
MNKD Looks 44.2% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
MNKD Looks 44.2% Undervalued on GF Value™ Amid Speculative Growt - GuruFocus
MannKind partners with Rose Pharma on inhaled GLP-1 therapy By Investing.com - Investing.com India
MannKind partners with Rose Pharma on inhaled GLP-1 therapy - investing.com
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management - The Manila Times
MannKind and Rose Pharma Enter Worldwide Collaboration to Develop Inhaled ROSE-010 Technosphere for Weight Management - Quiver Quantitative
MannKind and Rose Pharma Inc Enter Licensing and - GlobeNewswire
MannKind and Rose Pharma Inc Enter Licensing and - GlobeNewswire
A rapid-acting, short-duration inhaled treatment is being developed for weight management - stocktitan.net
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management - Yahoo Finance
Finanzdaten der Mannkind Corp-Aktie (MNKD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Mannkind Corp-Aktie (MNKD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| STEVEN BINDER | Director |
Sep 25 '26 |
Proposed Sale |
3.29 |
39,051 |
128,478 |
0 |
| STEVEN BINDER | Director |
Sep 10 '26 |
Proposed Sale |
3.94 |
33,558 |
132,219 |
0 |
| Binder Steven B. | Director |
Sep 10 '26 |
Sale |
3.81 |
33,558 |
127,856 |
752,309 |
| STEVEN BINDER | Director |
Aug 07 '26 |
Proposed Sale |
3.89 |
39,051 |
151,908 |
0 |
| Binder Steven B. | Director |
Aug 07 '26 |
Sale |
4.06 |
39,051 |
158,547 |
785,867 |
| Binder Steven B. | Director |
Jul 17 '26 |
Sale |
4.06 |
52,485 |
213,089 |
824,918 |
| DAVID THOMSON | Officer |
Jul 17 '26 |
Proposed Sale |
4.04 |
24,109 |
97,400 |
0 |
| STEVEN BINDER | Director |
Jul 17 '26 |
Proposed Sale |
4.04 |
52,485 |
212,039 |
0 |
| Thomson David | EVP Genl Counsel & Secretary |
Jul 17 '26 |
Sale |
4.05 |
24,109 |
97,641 |
797,554 |
| Tross Stuart A | Chief People & Workpl Officer |
Jul 15 '26 |
Option Exercise |
0.00 |
93,790 |
0 |
1,123,950 |
7.94%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):